

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A gene transfer vector comprising an exogenous gene encapsulated in a native virus envelope, wherein the genome of the virus is inactivated, and wherein the virus belongs to the herpesviridae family.
2. (previously presented) The gene transfer vector according to claim 1, wherein the virus is derived from a wild-type virus or a recombinant-type virus.
3. (canceled)
4. (withdrawn) The gene transfer vector according to claim 3, wherein the virus is HVJ.
5. (currently amended) The gene transfer vector according to claim 1, wherein the gene transfer vector is prepared by a method which comprises the steps of:  
mixing the virus with an exogenous gene; and  
inactivating the virus; and  
freezing and thawing the mixture two or more times.
6. (previously presented) The gene transfer vector according to claim 1, wherein the vector is prepared by a method which comprises a step of mixing the virus with an exogenous gene in the presence of a detergent.
7. (canceled)
8. (currently amended) The gene transfer vector according to claim 76, wherein the detergent is selected from the group consisting of octylglucoside, Triton-X100, CHAPS and NP-40.
9. (previously presented) The gene transfer vector according to claim 8, wherein the detergent is octylglucosidase.

10. (canceled)

11. (previously presented) The gene transfer vector according to claim 1 for introducing a gene into animal in vivo tissue.

12. (previously presented) The gene transfer vector according to claim 11, wherein the tissue is selected from the group consisting of the liver, skeletal muscles, the uterus, brain, eyes, carotid arteries, skin, blood vessels, the lung, the heart, kidneys, the spleen, cancer tissue, nerves, B lymphocytes, and respiratory tract tissue.

13. (currently amended) A pharmaceutical composition for gene therapy which comprises ~~at the~~ gene transfer vector of any one of claims 1-2, 5-6, 8-9, or 11-12 comprising ~~an exogenous gene encapsulated in a native virus envelope~~.

14. (currently amended) A kit for screening gene libraries, which comprises ~~at the~~ gene transfer vector of any one of claims 1-2, 5-6, 8-9, or 11-12 comprising ~~an exogenous gene encapsulated in a native virus envelope~~.

15. (canceled)

16. (currently amended) A method for preparing ~~at the~~ gene transfer vector of any one of claims 1-2, 5-6, 8-9, or 11-12 comprising ~~an exogenous gene encapsulated in a native virus envelope for gene transfer~~, wherein the method comprises the steps of: mixing the virus with the exogenous gene in the presence of a detergent; and inactivating the virus.

17. (canceled)

18. (currently amended) A method for introducing a gene into isolated animal tissue, wherein the method comprises the steps of:

preparing ~~at the~~ gene transfer vector of any one of claims 1-2, 5-6, 8-9, or 11-12 comprising ~~an exogenous gene encapsulated in a native virus envelope~~; and introducing the exogenous gene into the isolated animal tissue via the gene transfer vector.

19-22. (canceled)

23. (previously presented) The pharmaceutical composition according to claim 13, wherein the virus is derived from a wild-type or a recombinant-type virus.

24. (canceled)

25. (withdrawn) The pharmaceutical composition according to claim 13, wherein the virus is HVJ.

26. (previously presented) The kit according to claim 14, wherein the virus is derived from a wild-type or a recombinant-type virus.

27-29. (canceled)

30. (previously presented) The method according to claim 18, wherein said virus is derived from a wild-type or a recombinant-type virus.

31-32. (canceled)